Bispecific Antibody-HSA Fusion Proteins

Creative Biolabs can perform bispecific fusion protein engineering based on our rich experience in understanding target antigens and antibody application. With state-of-the art facilities, experienced scientists in antibody engineering field, Creative Biolabs is capable of providing various recombinant antibodies by fusing bispecific antibody (BsAb) with human serum albumin (HSA).

Figure: Schematic presentation of bispecific antibody-HSA fusion proteins (J Biol Chem, 2007)

Bispecific antibodies have been shown to be effective in immunotherapy for various diseases. However, the therapeutic efficacy of some BsAbs, such as single chain diabodies (scDb), tandem scFv (taFv) molecules, is hampered by the short serum half-life due to their small size. To solve this problem, scientists from Creative Biolabs fuse BsAbs with long-circulating serum proteins, such as human serum albumin (HSA), which has a high affinity and a strong stability, and therefore, it has been widely used in therapy and diagnostic researches. Thus, we employ HSA to construct recombinant BsAbs to achieve an increased serum half-life and improved pharmacokinetics without impairing their target binding capability and efficacy.

By leveraging advanced antibody engineering platforms, Creative Biolabs can offer bispecific antibody-HSA fusion proteins with the highest standard for quality.

Dafne Mu¨ller, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem. 2007 Apr 27; 282 (17):12650-60.

Online Inquiry
Please input "biolabs"(case insensitive) as verification code.
45-1 Ramsey Road, Shirley, NY 11967, USA     Tel: 1-631-381-2994    Fax: 1-631-207-8356    Email:
Terms of Service-Privacy Policy     © 2007 - 2018 Creative-Biolabs All Rights Reserved